Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results
In brief
Cemiplimab plus chemotherapy doubled median survival in PD-L1-positive lung cancer
Among 327 patients with advanced lung cancer and PD-L1 expression of at least 1%, median survival was 24 months with cemiplimab plus chemotherapy versus 12.1 months with chemotherapy alone after about five years of follow-up. Severe treatment-emergent side effects were more common with the combination, affecting 48.8% versus 27.5%; the benefit persisted across tumor types and PD-L1 levels.
- Journal
- ESMO open (Q1)
- Published
- 15 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- M Gogishvili, T Makharadze, T Melkadze, D Giorgadze, K Penkov, K Laktionov, et al.
- PMID
- 43035066
- DOI
- 10.1016/j.esmoop.2026.108623
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (paper of the day, 17 November 2026): Phase III RCT of cemiplimab + chemo in NSCLC
Abstract
BACKGROUND: EMPOWER-Lung 3 Part 2, a phase 3, double-blind, placebo-controlled study, demonstrated substantial survival benefits with cemiplimab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 alterations. Here, we report 5-year results from the subgroup analysis of patients with programmed death-ligand 1 (PD-L1) expression ≥1%. PATIENTS AND METHODS: Eligible patients were randomized 2 : 1 to receive histology-specific platinum-doublet chemotherapy plus cemiplimab 350 mg or placebo every 3 weeks for up to 108 weeks. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). This analysis focuses on patients with PD-L1 ≥1% with 5-year follow-up (last patient last visit: 27 February 2025). RESULTS: Of 327 patients with PD-L1 ≥1% (out of 466 in the overall study), 217 received cemiplimab plus chemotherapy and 110 received placebo plus chemotherapy. After median follow-up of 60.5 months, median OS for cemiplimab plus chemotherapy was 24.0 months [95% confidence interval (CI) 20.9-28.4] versus 12.1 months (95% CI 10.1-15.7) for placebo plus chemotherapy [hazard ratio (HR) 0.54, 95% CI 0.41-0.70, P < 0.0001); median PFS was 8.3 months (95% CI 6.7-10.8) versus 5.5 months (95% CI 4.3-6.2, HR 0.50, 95% CI 0.39-0.65, P < 0.0001), and the ORR was 48.4% versus 22.7%, respectively. Improved efficacy over placebo plus chemotherapy was observed across squamous and nonsquamous histologies, in both locally advanced and metastatic disease, and in patients with PD-L1 1%-49% and ≥50%. Grade ≥3 treatment-emergent adverse events occurred in 48.8% of patients receiving cemiplimab plus chemotherapy versus 27.5% receiving placebo plus chemotherapy. No new toxicities were identified. CONCLUSIONS: First-line cemiplimab plus chemotherapy continued to show durable clinical benefit versus placebo plus chemotherapy after 5 years of follow-up in PD-L1-positive advanced NSCLC.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.